Is Thymosin Alpha-1 Legal in Georgia?
At a glance
- FDA approval / None in the US; four orphan drug designations are not approvals [1]
- Authorized in / Italy, India and Hong Kong, per FDA's December 2024 review [1]
- State-licensed pharmacy bulks list / In none of the three categories [3]
- Outsourcing-facility bulks list / Category 3, nominated without adequate support [4]
- Advisory committee vote / 4 yes, 17 no, December 2024 [5]
- HHS peptide enforcement policy / Not one of the six covered peptides [2]
- Georgia-specific rule / Not established
What is its federal status?
A Drugs@FDA search found no US marketing application for thymosin alpha-1. FDA's December 2024 review notes four US orphan drug designations for it, which come from a separate process and are not approvals [1]. The finished injection sold outside the US is Zadaxin, 1.6 mg per vial, and it is not interchangeable with bulk thymosin alpha-1 powder [1].
Some other countries do authorize it. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation, for hepatocellular carcinoma, which is not a marketing approval [1].
Broader claims exist as well. A SciClone 2014 annual report says it is approved in parts of Asia-Pacific, Latin America, Eastern Europe and the Middle East, and FDA could not independently verify those claims [1]. Two older reviews by authors tied to the developer say it is approved in 'over 35 countries' (2009) and 'more than 30 countries' (2007) [6][7].
What has FDA said about compounding it?
FDA's page on bulk substances that may present significant safety risks, content dated April 22, 2026, lists thymosin alpha-1 in the 'nominated but withdrawn' table. It had been in category 2 and came off when the nominators withdrew [8]. FDA's concerns remain posted: a significant risk of immunogenicity for certain routes of administration, peptide impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [8].
FDA's list for state-licensed pharmacies, updated May 14, 2026, does not include it in any of its three categories, and FDA's category 1 policy does not apply to it [3]. The outsourcing-facility list, updated March 21, 2025, places it in category 3, 'nominated without adequate support' [4]. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate [5]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [2].
What about Georgia?
Georgia licenses pharmacies and prescribers under its own statutes and board rules. No Georgia-specific rule establishing that thymosin alpha-1 may be compounded or dispensed is identified here. The federal information is more specific: it is absent from FDA's categories for state-licensed pharmacies, and no FDA or HHS action allowing its compounding was found [3][2].
Is there an approved dose?
No US-approved dose exists. The Italian Zadaxin label says 1.6 mg is given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination [1]. That label also says the product is not for children and is contraindicated in pregnancy and breastfeeding [1].
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can a Georgia pharmacy compound thymosin alpha-1?
Is thymosin alpha-1 banned for athletes?
What dose of thymosin alpha-1 is used?
References
Show all 9 referencesHide references
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.